SLC5A2 and polycystic ovary syndrome: Furthermore, a similar non-significant difference in weight loss was reported in two RCTs that administered SGLT-2 inhibitors (empagliflozin 25 mg daily; canagliflozin 100 mg daily) monotherapy compared with MET in women with PCOS (38, 42).